...
首页> 外文期刊>Cancer Cell >Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia
【24h】

Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia

机译:减少线粒体凋亡引发驱动抗急性髓性白血病的BH3模拟物的抗性

获取原文
获取原文并翻译 | 示例
           

摘要

Acquired resistance to BH3 mimetic antagonists of BCL-2 and MCL-1 is an important clinical problem. Using acute myelogenous leukemia (AML) patient-derived xenograft (PDX) models of acquired resistance to BCL-2 (venetoclax) and MCL-1 (S63845) antagonists, we identify common principles of resistance and persistent vulnerabilities to overcome resistance. BH3 mimetic resistance is characterized by decreased mitochondrial apoptotic priming as measured by BH3 profiling, both in PDX models and human clinical samples, due to alterations in BCL-2 family proteins that vary among cases, but not to acquired mutations in leukemia genes. BCL-2 inhibition drives sequestered pro-apoptotic proteins to MCL-1 and vice versa, explaining why in vivo combinations of BCL-2 and MCL-1 antagonists are more effective when concurrent rather than sequential. Finally, drug-induced mitochondrial priming measured by dynamic BH3 profiling (DBP) identifies drugs that are persistently active in BH3 mimetic-resistant myeloblasts, including FLT-3 inhibitors and SMAC mimetics.
机译:对BCL-2和MCL-1的BH3模拟拮抗剂获得性耐药性是一个重要的临床问题。利用急性髓细胞白血病(AML)患者来源的异种移植(PDX)模型,我们确定了耐药的共同原则和克服耐药的持久脆弱性,该模型对BCL-2(venetoclax)和MCL-1(S63845)拮抗剂具有获得性耐药。在PDX模型和人类临床样本中,BH3模拟耐药性的特征是通过BH3谱测定线粒体凋亡启动减少,这是由于不同病例中BCL-2家族蛋白的改变,而不是白血病基因的获得性突变。BCL-2抑制将分离的促凋亡蛋白驱动至MCL-1,反之亦然,这解释了为什么在体内同时使用BCL-2和MCL-1拮抗剂比连续使用更有效。最后,通过动态BH3谱(DBP)测量的药物诱导线粒体启动识别出在BH3模拟耐药的成髓细胞中持续活跃的药物,包括FLT-3抑制剂和SMAC模拟物。

著录项

  • 来源
    《Cancer Cell》 |2020年第6期|共25页
  • 作者单位

    Dana Farber Canc Inst Dept Med Oncol 440 Brookline Ave M430 Boston MA 02215 USA;

    Dana Farber Canc Inst Dept Med Oncol 440 Brookline Ave M430 Boston MA 02215 USA;

    Dana Farber Canc Inst Dept Med Oncol 440 Brookline Ave M430 Boston MA 02215 USA;

    Dana Farber Canc Inst Dept Med Oncol 440 Brookline Ave M430 Boston MA 02215 USA;

    Dana Farber Canc Inst Dept Med Oncol 440 Brookline Ave M430 Boston MA 02215 USA;

    Dana Farber Canc Inst Dept Med Oncol 440 Brookline Ave M430 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst Dept Bioinformat &

    Data Sci Boston MA 02115 USA;

    Dana Farber Canc Inst Dept Med Oncol 440 Brookline Ave M430 Boston MA 02215 USA;

    Dana Farber Canc Inst Dept Med Oncol 440 Brookline Ave M430 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst Dept Bioinformat &

    Data Sci Boston MA 02115 USA;

    Harvard Med Sch Dana Farber Canc Inst Dept Bioinformat &

    Data Sci Boston MA 02115 USA;

    Dana Farber Canc Inst Dept Med Oncol 440 Brookline Ave M430 Boston MA 02215 USA;

    Dana Farber Canc Inst Dept Med Oncol 440 Brookline Ave M430 Boston MA 02215 USA;

    Harvard Med Sch Boston MA 02115 USA;

    Dana Farber Canc Inst Breast Tumor Immunol Lab Boston MA 02115 USA;

    Novartis Inst BioMed Res Inc Cambridge MA USA;

    Novartis Inst BioMed Res Inc Cambridge MA USA;

    Novartis Inst BioMed Res Inc Cambridge MA USA;

    Novartis Inst BioMed Res Inc Cambridge MA USA;

    Dana Farber Canc Inst Belfer Ctr Appl Canc Sci Boston MA 02115 USA;

    Dana Farber Canc Inst Dept Med Oncol 440 Brookline Ave M430 Boston MA 02215 USA;

    Dana Farber Canc Inst Dept Med Oncol 440 Brookline Ave M430 Boston MA 02215 USA;

    Dana Farber Canc Inst Dept Med Oncol 440 Brookline Ave M430 Boston MA 02215 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号